# EDGAR Filing Document

**Accession Number:** 0001262104
**File Stem:** 0001193125-23-003583
**Filing Date:** 2023-1
**Character Count:** 7445
**Document Hash:** 1b84bb2c402f12fba0734ec0b8c4c15f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-003583.hdr.sgml**: 20230106

**ACCESSION NUMBER**: 0001193125-23-003583

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230105

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20230106

**DATE AS OF CHANGE**: 20230106

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MEI Pharma, Inc.
- **CENTRAL INDEX KEY:** 0001262104
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 510407811
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-50484
- **FILM NUMBER:** 23515378

**BUSINESS ADDRESS:**
- **STREET 1:** 11455 EL CAMINO REAL
- **STREET 2:** SUITE 250
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
- **BUSINESS PHONE:** 858-369-7100

**MAIL ADDRESS:**
- **STREET 1:** 11455 EL CAMINO REAL
- **STREET 2:** SUITE 250
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MARSHALL EDWARDS INC
- **DATE OF NAME CHANGE:** 20030902

?xml version="1.0" encoding="utf-8" ? 8-K

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

------

### FORM 8-K

------

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): January 5, 2023

------

## MEI Pharma, Inc.

#### (Exact name of registrant as specified in its charter)

------

---

| | | |
|:---|:---|:---|
| **Delaware** | **000-50484** | **51-0407811** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(Commission**<br> **File Number)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

#### 11455 El Camino Real, Suite 250

#### San Diego, California 92130

#### (Address of principal executive offices) (Zip Code)

#### Registrant's telephone number, including area code: (858) 369-7100

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol** | **Name of each exchange**<br> **on which registered** |
| Common stock, $0.00000002 par value | MEIP | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

☐&nbsp;&nbsp;&nbsp;&nbsp; Emerging growth company

☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the Exchange Act.

------

---

| | |
|:---|:---|
| **Item 5.07.** | **Submission of Matters to a Vote of Security Holders.**  |

---

On January 5, 2023, MEI Pharma, Inc. (the "Company") held its Annual Meeting. There were represented at the Annual Meeting, by proxy, 84,582,374 shares of the Company's common stock, par value $0.00000002 per share ("Common Stock"), out of a total number of 133,260,865 shares of Common Stock outstanding and entitled to vote at the Annual Meeting. The Company's stockholders voted on the following five proposals at the Annual Meeting, casting their votes as described below.

**Proposal 1. – Election of Director.** The following individual, who was named as a nominee in the Company's definitive proxy statement relating to the Annual Meeting, was elected by the Company's stockholders by a plurality of votes cast to serve a three-year term on the Company's Board of Directors which will expire at the Company's annual meeting of stockholders for fiscal year 2026. Information on the vote relating to the director standing for election is set forth below:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Nominee** | **For** | **For** | **Withheld** | **Withheld** | **Broker Non-<br>Votes** | **Broker Non-<br>Votes** |
|  Dr. Thomas C. Reynolds |  | 49024478 |  | 5277845 |  | 30280051 |

---

**Proposal 2. – Approval of Amended and Restated 2008 Stock Omnibus Equity Compensation Plan.** Proposal 2 was to approve the Amended and Restated MEI Pharma, Inc. 2008 Omnibus Equity Compensation Plan (the "2008 Equity Plan") to increase the number of shares of common stock that may be subject to awards and to make certain other changes to the plan terms included in the plan document attached as Annex A to the definitive proxy statement relating to the Annual Meeting. The proposal was approved.

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-<br>Votes** |
| 44169994 | 5892604 | 4239725 | 30280051 |

---

**Proposal 3. – Approval of an Amendment to the Amended and Restated Certificate of Incorporation to Effect a Reverse Stock Split.** Proposal 3 was to approve an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stock split of our outstanding shares of common stock by a ratio of any whole number between 1-for-10 and 1-for-20, at any time prior to June 30, 2023, with the exact ratio to be set within that range at the discretion of our Board of Directors, without further approval or authorization of the Company's stockholders. The proposal was approved.

---

| | | |
|:---|:---|:---|
| **For** | **Against** | **Abstain** |
| 68495443 | 12271441 | 3815490 |

---

**Proposal 4. – Advisory Vote on Executive Compensation.** Proposal 4 was to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement. The proposal was approved.

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-<br>Votes** |
| 43376299 | 6778476 | 4147548 | 30280051 |

---

------

**Proposal 5. – Ratification of Appointment of BDO USA, LLP.** Proposal 5 was to ratify the appointment of BDO USA, LLP, an independent registered public accounting firm, as the Company's independent auditors for the fiscal year ending June 30, 2023. The proposal was approved.

---

| | | |
|:---|:---|:---|
| **For** | **Against** | **Abstain** |
| 78700571 | 689734 | 5192069 |

---

------

#### Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| MEI PHARMA, INC. | MEI PHARMA, INC. |
| By: | /s/ Daniel P. Gold |
|  | Daniel P. Gold |
|  | Chief Executive Officer |

---

Dated: January 6, 2023